Nebulised interferon beta-1a for patients with COVID-19

Type Journal Article Author Nathan Peiffer-Smadja Author Yazdan Yazdanpanah URL https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30523-3/abstract Series Comment Publication The Lancet Respiratory Medicine ISSN 2213-2600, 2213-2619 Date 12/11/2020 Extra Publisher: Elsevier PMID: 33189160 Journal Abbr The Lancet Respiratory Medicine DOI 10.1016/S2213-2600(20)30523-3 Library Catalog www.thelancet.com Language English Abstract In The Lancet Respiratory Medicine, Phillip Monk and colleagues1 report the results of a randomised, double-blind, placebo-controlled phase 2 pilot trial of nebulised interferon beta-1a in 101 adults admitted to hospital with COVID-19. The authors found that patients who received nebulised interferon beta-1a had significantly greater odds of clinical improvement across the WHO Ordinal Scale for Clinical Improvement than those who received placebo, both on day 15/16 (odds ratio [OR] 2·32 [95% CI 1·07–5·04]; p=0·033) and on day 28 (3·15 [1·39–7·14]; p=0·006).